(VIANEWS) – Middlefield Banc Corp. (MBCN), National Health Investors (NHI), TCG BDC (CGBD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Middlefield Banc Corp. (MBCN)
37.9% sales growth and 9.14% return on equity
Middlefield Banc Corp., headquartered in Middlefield, Ohio, is the bank holding company of The Middlefield Banking Company with total assets of $1.39 billion at March 31, 2021. The bank operates 16 full-service banking centers and an LPL Financial® brokerage office serving Beachwood, Chardon, Cortland, Dublin, Garrettsville, Mantua, Middlefield, Newbury, Orwell, Plain City, Powell, Solon, Sunbury, Twinsburg, and Westerville. The Bank also operates a Loan Production Office in Mentor, Ohio. Additional information is available at www.middlefieldbank.bank.
Earnings Per Share
As for profitability, Middlefield Banc Corp. has a trailing twelve months EPS of $2.59.
PE Ratio
Middlefield Banc Corp. has a trailing twelve months price to earnings ratio of 10.66. Meaning, the purchaser of the share is investing $10.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.14%.
2. National Health Investors (NHI)
28.8% sales growth and 4.67% return on equity
Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI's portfolio consists of independent, assisted and memory care communities, entrance-fee retirement communities, skilled nursing facilities, medical office buildings and specialty hospitals.
Earnings Per Share
As for profitability, National Health Investors has a trailing twelve months EPS of $1.48.
PE Ratio
National Health Investors has a trailing twelve months price to earnings ratio of 34.22. Meaning, the purchaser of the share is investing $34.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.67%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Mar 29, 2023, the estimated forward annual dividend rate is 3.6 and the estimated forward annual dividend yield is 7.24%.
Moving Average
National Health Investors’s worth is under its 50-day moving average of $54.80 and way under its 200-day moving average of $57.73.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.4%, now sitting on 278.76M for the twelve trailing months.
Yearly Top and Bottom Value
National Health Investors’s stock is valued at $50.64 at 16:22 EST, way below its 52-week high of $67.16 and above its 52-week low of $48.05.
3. TCG BDC (CGBD)
25.7% sales growth and 9.18% return on equity
TCG BDC, Inc. is a non-diversified closed-end investment company. The fund operates as a business development company. The company provides debt investments in the U.S. middle market companies. It also invests in first lien and second lien senior secured loans; middle market junior loans, such as corporate mezzanine loans, equity co-investments, syndicated first lien and second lien senior secured loans, high-yield bonds, structured finance obligations, and other opportunistic investments. The company was founded in 2012 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, TCG BDC has a trailing twelve months EPS of $1.49.
PE Ratio
TCG BDC has a trailing twelve months price to earnings ratio of 8.95. Meaning, the purchaser of the share is investing $8.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.18%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Mar 29, 2023, the estimated forward annual dividend rate is 1.76 and the estimated forward annual dividend yield is 13.2%.
Volume
Today’s last reported volume for TCG BDC is 104276 which is 58.47% below its average volume of 251130.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 23.1% and 4.3%, respectively.
Sales Growth
TCG BDC’s sales growth is 26.2% for the present quarter and 25.7% for the next.
4. Brown & Brown (BRO)
16.3% sales growth and 15.26% return on equity
Brown & Brown, Inc. markets and sells insurance products and services in the United States, Bermuda, Canada, Cayman Islands, Ireland, and the United Kingdom. It operates through four segments: Retail, National Programs, Wholesale Brokerage, and Services. The company offers builders risk, group medical and pharmaceutical, property, commercial auto, homeowners, reinsurance, crop and hail, inland marine, retirement benefit, cyber, disability, risk mitigating warranty products, directors and officers, management liability, errors and omissions, medical stop loss, term life, excess liability, personal auto, umbrella, general liability, prescription drug, workers compensation, and group dental insurance products. It also provides professional liability and related package insurance products for dentistry, legal, eyecare, insurance, financial, physicians, and real estate title professionals, as well as supplementary insurance-related products for weddings, events, medical facilities, and cyber liability; homeowners and personal property policies, residential earthquake, and private passenger automobile and motorcycle coverage; commercial and public entity-related programs; and flood insurance, commercial difference-in-conditions, all-risk commercial property, coastal property programs, lender-placed solutions, sovereign Indian nations, and parcel insurance. In addition, it provides markets and sells excess and surplus commercial insurance products, such as personal lines, homeowners, yachts, jewelry, commercial property and casualty, commercial automobile, garage, restaurant, builder's risk, and inland marine lines; and third-party claims administration and medical utilization management services in the workers' compensation and all-lines liability arenas, as well as Medicare Set-aside, Social Security disability, Medicare benefits advocacy, and claims adjusting services. The company was founded in 1939 and is headquartered in Daytona Beach, Florida.
Earnings Per Share
As for profitability, Brown & Brown has a trailing twelve months EPS of $2.38.
PE Ratio
Brown & Brown has a trailing twelve months price to earnings ratio of 23.26. Meaning, the purchaser of the share is investing $23.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.26%.
Sales Growth
Brown & Brown’s sales growth is 17.9% for the current quarter and 16.3% for the next.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Feb 1, 2023, the estimated forward annual dividend rate is 0.46 and the estimated forward annual dividend yield is 0.84%.
Volume
Today’s last reported volume for Brown & Brown is 928984 which is 20.55% below its average volume of 1169370.
5. Corcept Therapeutics Incorporated (CORT)
6% sales growth and 23.11% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $0.87.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 24.9. Meaning, the purchaser of the share is investing $24.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.11%.
Yearly Top and Bottom Value
Corcept Therapeutics Incorporated’s stock is valued at $21.66 at 16:22 EST, way under its 52-week high of $30.14 and way above its 52-week low of $17.19.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.3%, now sitting on 401.86M for the twelve trailing months.
Volume
Today’s last reported volume for Corcept Therapeutics Incorporated is 1148380 which is 46.71% above its average volume of 782743.
